SI1002795T1 - HIV Replication inhibiting pyrimidines - Google Patents

HIV Replication inhibiting pyrimidines

Info

Publication number
SI1002795T1
SI1002795T1 SI9930275T SI9930275T SI1002795T1 SI 1002795 T1 SI1002795 T1 SI 1002795T1 SI 9930275 T SI9930275 T SI 9930275T SI 9930275 T SI9930275 T SI 9930275T SI 1002795 T1 SI1002795 T1 SI 1002795T1
Authority
SI
Slovenia
Prior art keywords
hiv replication
replication inhibiting
inhibiting pyrimidines
pyrimidines
hiv
Prior art date
Application number
SI9930275T
Other languages
English (en)
Slovenian (sl)
Inventor
Corte Bart De
Jonge Marc Rene De
Jan Heeres
Chih Yung Ho
Paul Adriaan Jan Janssen
Robert W. Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Aken Koen Jeanne Alfons Van
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1002795(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI1002795T1 publication Critical patent/SI1002795T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI9930275T 1998-11-10 1999-11-01 HIV Replication inhibiting pyrimidines SI1002795T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines
EP99203590A EP1002795B1 (en) 1998-11-10 1999-11-01 HIV Replication inhibiting pyrimidines

Publications (1)

Publication Number Publication Date
SI1002795T1 true SI1002795T1 (en) 2003-10-31

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930275T SI1002795T1 (en) 1998-11-10 1999-11-01 HIV Replication inhibiting pyrimidines

Country Status (41)

Country Link
US (5) US6878717B2 (cg-RX-API-DMAC10.html)
EP (2) EP1002795B1 (cg-RX-API-DMAC10.html)
JP (1) JP3635238B2 (cg-RX-API-DMAC10.html)
KR (1) KR100658489B1 (cg-RX-API-DMAC10.html)
CN (1) CN1214013C (cg-RX-API-DMAC10.html)
AP (1) AP1683A (cg-RX-API-DMAC10.html)
AR (1) AR024227A1 (cg-RX-API-DMAC10.html)
AT (2) ATE455107T1 (cg-RX-API-DMAC10.html)
AU (2) AU762523C (cg-RX-API-DMAC10.html)
BG (1) BG65103B1 (cg-RX-API-DMAC10.html)
BR (1) BRPI9915552B8 (cg-RX-API-DMAC10.html)
CA (1) CA2350801C (cg-RX-API-DMAC10.html)
CY (1) CY2008021I1 (cg-RX-API-DMAC10.html)
CZ (1) CZ301367B6 (cg-RX-API-DMAC10.html)
DE (3) DE69905683T2 (cg-RX-API-DMAC10.html)
DK (1) DK1002795T3 (cg-RX-API-DMAC10.html)
EA (1) EA004049B1 (cg-RX-API-DMAC10.html)
EE (1) EE05086B1 (cg-RX-API-DMAC10.html)
ES (2) ES2193664T3 (cg-RX-API-DMAC10.html)
FR (1) FR09C0004I2 (cg-RX-API-DMAC10.html)
HK (1) HK1048817B (cg-RX-API-DMAC10.html)
HR (2) HRP20010161B9 (cg-RX-API-DMAC10.html)
HU (2) HU227453B1 (cg-RX-API-DMAC10.html)
ID (1) ID28376A (cg-RX-API-DMAC10.html)
IL (2) IL143023A0 (cg-RX-API-DMAC10.html)
LT (1) LTC1002795I2 (cg-RX-API-DMAC10.html)
LU (1) LU91528I2 (cg-RX-API-DMAC10.html)
MY (1) MY121108A (cg-RX-API-DMAC10.html)
NL (1) NL300373I2 (cg-RX-API-DMAC10.html)
NO (3) NO318801B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ511116A (cg-RX-API-DMAC10.html)
OA (1) OA11674A (cg-RX-API-DMAC10.html)
PL (1) PL204427B1 (cg-RX-API-DMAC10.html)
PT (1) PT1002795E (cg-RX-API-DMAC10.html)
SI (1) SI1002795T1 (cg-RX-API-DMAC10.html)
SK (2) SK287270B6 (cg-RX-API-DMAC10.html)
TR (1) TR200101306T2 (cg-RX-API-DMAC10.html)
TW (1) TWI238161B (cg-RX-API-DMAC10.html)
UA (1) UA70966C2 (cg-RX-API-DMAC10.html)
WO (1) WO2000027825A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200103769B (cg-RX-API-DMAC10.html)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227453B1 (en) * 1998-11-10 2011-06-28 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines, and pharmaceutical compositions containing them
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
WO2001022938A1 (en) * 1999-09-24 2001-04-05 Janssen Pharmaceutica N.V. Antiviral compositions
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
AU782948B2 (en) 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines
JP5230050B2 (ja) * 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
US7039697B2 (en) * 2000-11-01 2006-05-02 Snapnames.Com Inc. Registry-integrated internet domain name acquisition system
MEP13408A (en) 2001-05-29 2010-06-10 Bayer Schering Pharma Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
UY27487A1 (es) * 2001-10-17 2003-05-30 Boehringer Ingelheim Pharma Derivados de pirimidina, medicamentos que contienen estos compuestos, su empleo y procedimiento para su preparación
NZ531855A (en) 2001-11-01 2005-12-23 Janssen Pharmaceutica Nv Amide derivatives as glycogen synthase kinase 3-beta inhibitors
EA010859B1 (ru) 2001-11-01 2008-12-30 Янссен Фармацевтика Н.В. Гетероариламины - производные пиримидина и пиридазина в качестве ингибиторов гликогенсинтаза-киназы 3-бета (ингибиторов gsk3)
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4725945B2 (ja) 2002-03-13 2011-07-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのスルホニルアミノ誘導体
WO2003076400A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
NZ536294A (en) * 2002-05-03 2005-05-27 Janssen Pharmaceutica Nv Polymeric microemulsions of amphiphilic diblock copolymers
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
RS51752B (sr) 2002-07-29 2011-12-31 Rigel Pharmaceuticals Metode tretiranja i prevencije autoimunih oboljenja jedinjenjima 2,4-pirimidindiamina
ES2422196T3 (es) * 2002-08-09 2013-09-09 Janssen Pharmaceutica Nv Procesos para la preparación de 4-4-4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)aminobenzonitrilo
WO2004026283A1 (en) 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
RS20050363A (sr) * 2002-11-28 2007-11-15 Schering Aktiengesellschaft, Chk-,Pdk- I Akt-INHIBITORNI PIRIMIDINI, NJIHOVA PROIZVODNJA I UPOTREBA KAO FARMACEUTSKIH SREDSTAVA
NZ540612A (en) 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
ES2311146T3 (es) 2003-02-07 2009-02-01 Janssen Pharmaceutica Nv 1,2,4-triazinas que inhiben el vih.
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
DE602004021472D1 (en) 2003-02-20 2009-07-23 Smithkline Beecham Corp Pyrimiidinverbindungen
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
EP1648467B1 (en) 2003-07-17 2018-03-21 Janssen Sciences Ireland UC Process for preparing particles containing an antiviral
RS53109B (sr) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. Jedinjenja 2,4 pirimidindiamina za upotrebu u tretmanu ili prevenciji autoimunih bolesti
ATE500254T1 (de) * 2003-09-25 2011-03-15 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
EP1728186A2 (en) 2004-03-02 2006-12-06 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
NZ552865A (en) 2004-07-28 2009-09-25 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CN101035773B (zh) 2004-08-10 2012-06-06 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
EP1797047B1 (en) * 2004-09-30 2012-01-25 Tibotec Pharmaceuticals Hiv inhibiting 5-substituted pyrimidines
CN101031550B (zh) 2004-09-30 2015-05-27 泰博特克药品有限公司 抑制hiv的5-碳环-或杂环取代的嘧啶类
US8575342B2 (en) 2004-09-30 2013-11-05 Tibotech Pharmaceuticals Ltd. HIV inhibiting 5-heterocyclyl pyrimidines
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
JP2008519073A (ja) * 2004-11-08 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
KR101278397B1 (ko) 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. 2,4-피리미딘디아민 화합물의 전구약물 및 이의 용도
RU2403245C2 (ru) * 2005-01-27 2010-11-10 Тиботек Фармасьютикалз Лтд. Ингибирующие вич производные 2-(4-цианофениламино)пиримидина
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
EP1853567B1 (en) 2005-02-18 2014-12-31 Janssen R&D Ireland Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
PT1858861E (pt) 2005-03-04 2010-09-16 Tibotec Pharm Ltd 2-(4-cianofenil)-6-hidroxilaminopirimidinas inibidoras do hiv
AU2006248780B2 (en) 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ME01612B (me) 2005-05-26 2014-09-20 Janssen Sciences Ireland Uc Proces za pripremu 4-[(1,6-dihidro-6-okso-2-pirimidinil)amino benzonitrila
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN101355939A (zh) * 2005-10-06 2009-01-28 马萨诸塞大学 用于抑制hiv复制的新物质的组合物和合成
EP1945631B8 (en) 2005-10-28 2013-01-02 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
ES2327972T3 (es) 2006-01-19 2009-11-05 Janssen Pharmaceutica, N.V. Derivados de aminofenil como nuevos inhibidores de histona deacetilasa.
JP5137849B2 (ja) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
EP1979326B1 (en) 2006-01-19 2012-10-03 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
JP5070278B2 (ja) 2006-03-30 2012-11-07 テイボテク・フアーマシユーチカルズ Ｈｉｖを阻害する５−（ヒドロキシメチレンおよびアミノメチレン）置換されたピリミジン
AU2007233737B2 (en) * 2006-03-30 2012-11-29 Janssen Sciences Ireland Uc HIV inhibiting 5-amido substituted pyrimidines
PE20080068A1 (es) 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
ES2372983T3 (es) 2006-06-06 2012-01-30 Tibotec Pharmaceuticals Proceso para preparar formulaciones secadas por aspersión de tmc125.
KR20140079441A (ko) 2006-06-19 2014-06-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
ES2624593T3 (es) * 2006-12-06 2017-07-17 Janssen Sciences Ireland Uc Sal de hidrobromuro de un compuesto anti-VIH.
ES2470570T3 (es) * 2006-12-29 2014-06-24 Janssen R&D Ireland Pirimidinas sustituidas en posición 6 inhibidoras del HIV
EP2114902B1 (en) 2006-12-29 2014-09-17 Janssen R&D Ireland Hiv inhibiting 5,6-substituted pyrimidines
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
AU2008338442A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
BRPI0914682B8 (pt) 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
CA2757228C (en) 2009-03-30 2018-01-02 Tibotec Pharmaceuticals Co-crystal of etravirine and nicotinamide
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
JP5406934B2 (ja) * 2009-06-22 2014-02-05 エムキュア ファーマシューティカルズ リミテッド ジアリールピリミジン非ヌクレオシド系逆転写酵素阻害剤の合成方法
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
MX2012014158A (es) 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
EP2584901A4 (en) 2010-06-28 2013-10-09 Hetero Research Foundation PROCESS FOR PREPARING THE INTERMEDIATE OF STRAIN AND STRAIN OF POLYMORPHS
NZ607845A (en) 2010-08-10 2015-03-27 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN103269704B (zh) 2010-11-01 2018-07-06 西建卡尔有限责任公司 杂环化合物和其用途
EP2637502B1 (en) 2010-11-10 2018-01-10 Celgene CAR LLC Mutant-selective egfr inhibitors and uses thereof
PT3124483T (pt) 2010-11-10 2019-10-02 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2
PT2702045T (pt) 2011-04-26 2018-01-11 Mylan Laboratories Ltd Método inovador para a preparação de etravirina
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
DK2748166T3 (en) 2011-08-23 2018-10-29 Asana Biosciences Llc PYRIMIDO-PYRIDAZINON COMPOUNDS AND USE THEREOF
WO2013059572A1 (en) 2011-10-19 2013-04-25 Assia Chemical Industries Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
TW201325593A (zh) 2011-10-28 2013-07-01 Celgene Avilomics Res Inc 治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
JP6317320B2 (ja) 2012-03-15 2018-04-25 セルジーン シーエーアール エルエルシー 上皮成長因子受容体キナーゼ阻害剤の塩
CN108658873B (zh) 2012-03-15 2021-09-14 西建卡尔有限责任公司 表皮生长因子受体激酶抑制剂的固体形式
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US20150336900A1 (en) * 2012-10-29 2015-11-26 Biophore India Pharmaceuticals Pvt. Ltd. Process for the Synthesis of Etravirine and Its Intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
EP2935226A4 (en) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc HETEROARYL COMPOUNDS AND USES THEREOF
AU2013362755B2 (en) 2012-12-21 2018-09-13 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
CA2900012A1 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
CN118105392A (zh) 2017-04-28 2024-05-31 自由生物有限公司 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
JP2022539208A (ja) 2019-07-03 2022-09-07 スミトモ ファーマ オンコロジー， インコーポレイテッド チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
EP0172786B1 (de) * 1984-06-25 1991-01-30 Ciba-Geigy Ag Pyrimidinderivate wirksam als Schädlingsbekämpfungsmittel
HU206328B (en) 1988-03-31 1992-10-28 Mitsubishi Chem Ind Process for producing 6-substituted pyrimidine derivatives and antiviral phqrmaceutical compositions containing them as active components
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
KR20010041015A (ko) 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
ES2361146T3 (es) * 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
CZ299380B6 (cs) * 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
HU227453B1 (en) * 1998-11-10 2011-06-28 Janssen Pharmaceutica Nv Hiv replication inhibiting pyrimidines, and pharmaceutical compositions containing them
AU782948B2 (en) * 2000-05-08 2005-09-15 Janssen Pharmaceutica N.V. Prodrugs of HIV replication inhibiting pyrimidines

Also Published As

Publication number Publication date
OA11674A (en) 2005-01-12
NL300373I1 (nl) 2009-03-02
HUP0104177A2 (hu) 2002-03-28
BR9915552B1 (pt) 2013-11-19
HK1048817A1 (en) 2003-04-17
NO2009003I2 (no) 2010-06-07
ATE455107T1 (de) 2010-01-15
BR9915552A (pt) 2001-08-14
US8003789B2 (en) 2011-08-23
HUP0104177A3 (en) 2003-01-28
AU762523B2 (en) 2003-06-26
US6878717B2 (en) 2005-04-12
NO20011696L (no) 2001-04-04
IL169949A (en) 2011-02-28
HK1025330A1 (en) 2000-11-10
AR024227A1 (es) 2002-09-25
AU2011200708A1 (en) 2011-03-10
CZ20011533A3 (cs) 2001-10-17
CN1214013C (zh) 2005-08-10
FR09C0004I2 (fr) 2010-06-11
HK1048817B (en) 2010-04-09
BG105418A (en) 2001-11-30
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
LTC1002795I2 (lt) 2021-06-10
NO2021015I1 (no) 2021-03-29
NZ511116A (en) 2003-08-29
AU6200899A (en) 2000-05-29
US7037917B2 (en) 2006-05-02
LTPA2008016I1 (lt) 2021-04-26
US8530655B2 (en) 2013-09-10
HRP20080359A2 (en) 2008-12-31
ID28376A (id) 2001-05-17
NO20011696D0 (no) 2001-04-04
HRP20010161A2 (en) 2002-02-28
EP1002795A1 (en) 2000-05-24
NL300373I2 (nl) 2009-04-01
CY2008021I2 (el) 2010-07-28
EA200100536A1 (ru) 2002-02-28
ATE233740T1 (de) 2003-03-15
PL204427B1 (pl) 2010-01-29
EP1270560A1 (en) 2003-01-02
US20080176880A1 (en) 2008-07-24
CZ301367B6 (cs) 2010-02-03
CA2350801C (en) 2008-05-20
KR20010075235A (ko) 2001-08-09
NO2009003I1 (no) 2009-03-09
BG65103B1 (bg) 2007-02-28
EP1002795B1 (en) 2003-03-05
PT1002795E (pt) 2003-07-31
CN1322198A (zh) 2001-11-14
UA70966C2 (uk) 2004-11-15
HU227453B1 (en) 2011-06-28
ES2193664T3 (es) 2003-11-01
ES2338760T3 (es) 2010-05-12
LU91528I2 (fr) 2009-04-20
EE05086B1 (et) 2008-10-15
LU91528I9 (cg-RX-API-DMAC10.html) 2019-01-02
US20110263625A1 (en) 2011-10-27
US20040039005A1 (en) 2004-02-26
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
CA2350801A1 (en) 2000-05-18
IL143023A0 (en) 2002-04-21
US20050288278A1 (en) 2005-12-29
HU230394B1 (hu) 2016-04-28
EE200100252A (et) 2002-10-15
JP3635238B2 (ja) 2005-04-06
FR09C0004I1 (cg-RX-API-DMAC10.html) 2009-02-27
HRP20010161B1 (en) 2009-03-31
WO2000027825A1 (en) 2000-05-18
HRP20010161B9 (hr) 2014-10-24
PL347586A1 (en) 2002-04-08
KR100658489B1 (ko) 2006-12-18
NO318801B1 (no) 2005-05-09
SK287269B6 (sk) 2010-05-07
TR200101306T2 (tr) 2001-10-22
ZA200103769B (en) 2002-08-12
DE69905683T2 (de) 2004-03-18
JP2002529456A (ja) 2002-09-10
EA004049B1 (ru) 2003-12-25
EP1270560B1 (en) 2010-01-13
CY2008021I1 (el) 2010-07-28
BRPI9915552B8 (pt) 2021-05-25
SK6032001A3 (en) 2002-01-07
DE122009000003I1 (de) 2009-05-20
HRP20080359B1 (hr) 2016-01-01
DE69941934D1 (de) 2010-03-04
AP1683A (en) 2006-11-29
AU762523C (en) 2004-02-12
MY121108A (en) 2005-12-30
TWI238161B (en) 2005-08-21

Similar Documents

Publication Publication Date Title
IL143023A0 (en) Hiv replication inhibiting pyrimidines
AP2000001912A0 (en) Hiv inhibiting pyrimidine derivatives
EG24684A (en) HIV replication inhibiting pyrimidines
DE59902573D1 (en) Dihydropyrimidine
IL153754A0 (en) Pyrimidine derivatives
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
ZA992322B (en) Phosphodiesterase iv-inhibiting diazepinoindoles.
AU2792102A (en) Pyrimidine derivatives
IL141844A0 (en) Antiviral combinations
MXPA03000504A (es) Derivados de pirimidina.
DE69940886D1 (en) Hiv impfstoff
GB9820417D0 (en) Antiviral combinations
GB9821000D0 (en) Antiviral combinations
GB9820416D0 (en) Antiviral combinations
ZA200007155B (en) Uracil compounds and use thereof.
CA84129S (en) Portfolio
ZA200100906B (en) Uracil compounds and use thereof.
EP0954316A4 (en) PYRIMIDINE DERIVATIVES
IL150715A0 (en) Substituted pyrimidines
GB9810027D0 (en) Incinerator
SI1303496T1 (sl) Pirimidinski derivati
GB9820999D0 (en) Antiviral combinations
GB9827109D0 (en) Antiviral combinations